KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Total Current Liabilities

Last Annual Value

9.71M

3-Year CAGR

20%

5-Year CAGR

-5%

10-Year CAGR

-2%

KT

Kalaris Therapeutics Inc Competitors Analysis of Total Current Liabilities

KLRS · NASDAQ
CompanyTotal Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
9.71M
35.1%-23.8%N/A 
8.29M
-10.3%-10.9%8.3%
13.09M
2.3%-7.5%N/A
7.05M
-14.9%-22.1%N/A
8.02M
24.1%21.5%N/A
22.93M
-30.7%-1.8%N/A
22.90M
4.6%1.4%8.8%
24.55M
-12.0%9.9%N/A
18.33M
17.9%-5.0%N/A
10.09M
-25.6%2.6%N/A
19.09M
-29.0%23.4%18.1%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7